Q-omics provides the consensus-scored MAB21L4 profile across patient tissues and cancer cell-line models. MAB21L4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAB21L4 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MAB21L4 protein abundance shows 16,895 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where MAB21L4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAB21L4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAB21L4 survival associations across molecular data types. MAB21L4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAB21L4 RNA expression–survival associations across cancer types. High MAB21L4 expression shows unfavorable associations in ACC, DLBC, SKCM, CHOL and LUSC, but favorable associations in KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAB21L4 RNA expression.
This table summarizes MAB21L4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MAB21L4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAB21L4 shows lower tumor expression in HNSC, KIRC, KIRP, KICH, LUSC and LUAD. The HNSC box plot shows higher MAB21L4 RNA expression in normal versus tumor tissue (log2 FC = −4.170, t-test p < 0.001).
This table shows molecular features associated with MAB21L4 in patient tissues and cancer cell lines. In patient samples, MAB21L4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MAB21L4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
